Class / Patent application number | Description | Number of patent applications / Date published |
514425000 | Plural chalcogens bonded directly to the five-membered hetero ring by nonionic bonding | 40 |
20080207734 | Novel alkoxylactones, alkoxylactams and alkoxythiolactams for controlling processes based on microbial interaction - Compounds of the Formula I, | 08-28-2008 |
20080269317 | Compounds for Covalent Binding to MD-2 and Effect on the Immune Response - Compounds having a hydrophobic group with a group and capable of reacting with the cysteine residue for the binding to protein MD-2 are disclosed. The compounds are capable of covalently binding to MD-2, which can be either free or in the complex with other molecules. The compounds are capable of replacing other ligands or preventing a binding of other ligands, especially bacterial endotoxin (lipopolysaccharide-LPS), which can otherwise lead towards unwanted activation of the immune response and acute or chronic inflammatory diseases. | 10-30-2008 |
20080280972 | Iminosugar treatment of tumors - A proliferation of cells can be reduced by contacting the cells with a compound having formula (I) | 11-13-2008 |
20090012152 | Use of Tetramic Acid Derivatives for Controlling Insects from the Genus of the Plane Lice (Sternorrhyncha) - The present invention relates to the use of tetramic acid derivatives of the formula (I) | 01-08-2009 |
20090030065 | Use of Pde1c and Inhibitors Thereof - The present invention relates to the use of PDE1C as a novel target for the identification of compounds, which can be used for the treatment of pulmonary hypertension, fibrotic lung diseases or other fibrotic diseases outside the lung. The present invention further relates to the use of PDE1C inhibitors in the manufacture of pharmaceutical compositions for use in the therapy of those diseases. | 01-29-2009 |
20090048330 | Compound from Antrodia camphorata and the use thereof - The present invention relates to novel compounds from | 02-19-2009 |
20090069405 | TREATMENT OF CNS AND PAIN DISORDERS - A method of treating a patient suffering from a condition or disorder selected from chronic pain, neuropathic pain, fibromyalgia, migraine, bipolar disorder and depression comprises the administration of a pharmacologically effective amount of 3-(phenylmethylamino-methylene)pyrrolidine-2,4-dione (I) or a pharmaceutically acceptable salt or prodrug or solvate thereof. Also disclosed is the use of (I) for the manufacture of a pharmaceutical composition for treatment of such condition or disorder. | 03-12-2009 |
20090069406 | Analogs of tetramic acid - Tetramic acid analogues of Formula I and Formula II have antibacterial activity, primarily against gram-positive bacteria, and are iron chelators. | 03-12-2009 |
20090176861 | Cathepsin cysteine protease inhibitors - The present invention relates to a novel class of compounds mainly, substituted leucinamide-carboxylate derivatives of formula (I) wherein X is O or NR | 07-09-2009 |
20090306174 | Novel Five-Membered Iminocyclitol Derivatives as Selective and Potent Glycosidase Inhibitors: New Structures for Antivirals and Osteoarthritis Therapeutics - Novel 5-membered iminocyclitol derivatives were found to be a potent and selective inhibitors of the glycoprotein processing α- and β-glucosidase which were further found to be active antiviral agents against Japanese encephalitis virus, dengue virus serotype 2 (DEN-2), human SARS coronavirus and human β-hexosaminidase, a new target for development of osteoarthritis therapeutics. | 12-10-2009 |
20100022615 | ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS - Activated cytotoxic compounds are described for attachment to targeting molecules for the treatment of a mammalian disease condition which comprise, an activator, a spacer linker, a linker (e.g., self-immolative), and a cytotoxic drug selected from the group consisting of AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES, AMINO-AND-HYDROXY SUBSTITUTED STYRYLSULFONANILIDES, and SUBSTITUTED PHENOXY- AND PHENYLTHIO-STYRYLSULFONE DERIVATIVES. Activated cytotoxic compound attached to a targeting molecule are described wherein the targeting molecule is selected from the group consisting essentially of an antibody, a receptor, a ligand, a cytokine, a hormone, and a signal transduction molecule. The invention is further directed to a method of treatment of disease conditions. | 01-28-2010 |
20100099736 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT - The invention discloses the use of a compound of formula (I), wherein R | 04-22-2010 |
20100130584 | NOVEL COMPOUNDS FROM ANTRODIA CAMPHORATA - Compounds isolated from the fruiting body of | 05-27-2010 |
20100152277 | DIACYLGLYCEROL ACYLTRANSFERASE ASSAY - The present invention generally provides a method of measuring the biological activity of diacylglycerol acyltransferase (DGAT). Specifically, the present invention provides a method for rapid, mass screening of compounds which are able to modulate the biological activity of DGAT. More specifically, the present invention provides an assay system for measuring DGAT activity based on the use of particular micelles with the FlashPlate™ technology. | 06-17-2010 |
20100160409 | Highly Branched Reagents For Modifying Biopharmaceuticals, Their Preparation And Use - The invention relates to compounds, which are suitable for coupling to pharmaceuticals, in particular biopharmaceuticals, in addition to conjugates from the compounds comprising biomolecules or pharmaceutically active substances. The inventive compounds are highly cross-linked and can be formed in a simple manner by using a central cross-linking module. The invention also relates to the use of conjugates as an improved formulation of pharmaceuticals and to the production thereof. | 06-24-2010 |
20100179211 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION - The present invention relates to the use of compounds which increase extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically to the use of 3-disubstituted phenyl-1-pyrrolidinols for the treatment of central nervous system disorders. | 07-15-2010 |
20110077282 | NOVEL COMPOUNDS FROM ANTRODIA CAMPHORATA - Disclosed herein are isolated compounds or pharmaceutically acceptable salts thereof, which exhibit immunostimulatory or anti-inflammatory effects. The compounds are isolated from the fruiting body of | 03-31-2011 |
20110098336 | PYRROLIDIN-2-ONE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR - A compound represented by the formula (I) according to claim | 04-28-2011 |
20110201666 | COMPOUNDS FROM MYCELIUM OF ANTRODIA CINNAMOMEA AND USE THEREOF - The present invention relates to compounds from mycelium of | 08-18-2011 |
20110257242 | 3-PHENYL-3-METHOXYPYRROLIDINE DERIVATIVES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION - The present invention relates to novel 3-phenyl-3-methoxy-pyrrolidine derivatives, useful for modulating dopamine neurotransmission and extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders. In other aspects the invention relates to pharmaceutical compositions comprising the 3-phenyl-3-methoxy-pyrrolidine derivatives of the invention and to the use of these compounds for therapeutic applications. | 10-20-2011 |
20110301217 | Selective Glycosidase Inhibitors and Uses Thereof - The application relates to an immoalditol compound for selectively inhibiting glycosidases, a prodrug thereof and a pharmaceutical composition comprising the compound or the prodrug The application also relates to the use of the immoalditol compound for treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc Such diseases and disorders include neurodegenerative diseases, tauopathy, cancers, and cardiac disorders | 12-08-2011 |
20120016001 | SUCCINIMIDE DERIVATIVES AS OCULAR HYPOTENSIVE AGENTS - The present invention provides methods and pharmaceutical compositions for treating ocular disorders associated with elevated intraocular pressure, such as glaucoma, by administering antiepileptic or anti-convulsant compounds of the succinimide family, in particular compounds of formula I and/or II as defined herein. | 01-19-2012 |
20120046337 | Novel Five-Membered Iminocyclitol Derivatives as Selective and Potent Glycosidase Inhibitors: New Structures for Antivirals and Osteoarthritis Therapeutics - Novel 5-membered iminocyclitol derivatives were found to be a potent and selective inhibitors of the glycoprotein processing α- and β-glucosidase which were further found to be active antiviral agents against Japanese encephalitis virus, dengue virus serotype 2 (DEN-2), human SARS coronavirus and human β-hexosaminidase, a new target for development of osteoarthritis therapeutics. | 02-23-2012 |
20120149753 | USE OF NOVEL COMPOUNDS FROM FRUITING BODY OF ANTRODIA CAMPHORATA FOR TREATING AN INFLAMMATORY DISORDER - Disclosed herein are isolated compounds or pharmaceutically acceptable salts thereof, which exhibit immunostimulatory or anti-inflammatory effects. The compounds are isolated from the fruiting body of | 06-14-2012 |
20120258997 | NEW APPLICATION OF 2-PYRROLIDONE DERIVATIVES - The invention is related to the new application of selected derivatives of 2-pyrrolidone to inhibition of protein glycation and to prevention and treatment of diabetes complications, such as atherosclerosis, nephropathy, retinopathy, cataract or neuropathy. | 10-11-2012 |
20130059900 | CRYSTAL FORM I OF (S)-4-HYDROXY-2-OXO-1-PYRROLIDINE ACETAMIDE, PREPARING METHOD AND USE THEREOF - A crystal form I of (S)-4-hydroxy-2-oxo-1-pyrrolidine acetamide, or named (S)-oxiracetam, is provided, which is characterized by a powder x-ray diffraction pattern that exhibits data of d-values versus the relative intensities as: 7.075(M), 5.355(S), 5.092(S), 4.590(M), 4.325(M), 4.259(S), 4.041(VS), 3.808(M), 3.542(M), 3.445(M), 3.393(M), 2.972(M), 2.914(S). A method for preparing a crystal form I of (S)-oxiracetam is also provided, which includes preparing the crude product and crystallizing A use of the crystal form I of (S)-oxiracetam in the manufacture of a medicament for preventing and treating memory dysfunction is also provided. Accordingly, the crystal form I of (S)-oxiracetam prepared by the method has high purity of more than 99.3% based on the percentages of the mass, with better efficacy than (S)-oxiracetam for preventing or treating memory dysfunction. Concerning the way of charging materials, adding inorganic base only a few times is simpler and more beneficial to industrial manufacturing and application. | 03-07-2013 |
20130109735 | SALACINOL AND PONKORANOL HOMOLOGUES, DERIVATIVES THEREOF, AND METHODS OF SYNTHESIZING SAME | 05-02-2013 |
20130281507 | METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES - The invention relates to compounds of formula (I): The invention likewise relates to a cosmetic method for depigmenting, lightening and/or whitening keratin materials, more particularly the skin, that utilizes these compounds | 10-24-2013 |
20130296398 | USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY - The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which•modifies low-threshold or transient neuronal calcium currents,or•reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate. | 11-07-2013 |
20140005248 | NOVEL CHOLECYSTOKININ RECEPTOR LIGANDS | 01-02-2014 |
20140128446 | 2-Methylthiopyrrolidines and Their Use for Modulating Bacterial Quorum Sensing - Compounds of Formula (I) are disclosed herein and their use in inhibiting quorum sensing in bacteria. | 05-08-2014 |
20140155456 | USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY - The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which•modifies low-threshold or transient neuronal calcium currents,or•reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate. | 06-05-2014 |
20140155457 | Method of Relieving, Improving, Preventing or Treating Xerostomia - Provided is a method of relieving, improving, preventing or treating xerostomia including applying an oral cavity composition including a polyethylene glycol (PEG) derivative whose reactor is modified to form a covalent bond with an epithelial cell of the oral cavity. An oral moisturizing effect and moisture persistency are increased and the method is effective against xerostomia due to aging or disease. | 06-05-2014 |
20140275205 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES - The present invention provides compounds of formula (I), | 09-18-2014 |
20140275206 | USE OF LEVO-OXIRACETAM AND OXIRACETAM IN PREPARATION OF MEDICINES FOR PREVENTING OR TREATING COMA - The present invention is to provide uses of the L-oxiracetam in preparation of medicines for preventing or treating coma. Experimental results show that L-oxiracetam wake-promoting effects of alcoholism-induced coma is obvious, and D-oxiracetam has basically no effect. The effect of the above wake-promoting effects of L-oxiracetam is 2 times greater than racemic oxiracetam. The wake-promoting effects of L-oxiracetam on trauma or anesthesia-induced coma are both significant. | 09-18-2014 |
20140343117 | METHODS AND PRODUCTS TO DIAGNOSE AND TREAT HEATINESS - Described herein are methods of diagnosing and/or classifying heatiness, a syndrome recognized in traditional Chinese Medicine, comprising assessing a patient by checking for selected symptoms, and assigning a score to the patient based on the symptoms exhibited. The invention further provides methods of treatment and the use of oral care compositions to treat heatiness. | 11-20-2014 |
20150087688 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS - The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a biologically active moiety-linker conjugate D-L, wherein D is a hydroxyl-comprising biologically active moiety; and L is a promoiety comprising a moiety L | 03-26-2015 |
20150119442 | Biocide agents against marine woodborers - The present invention relates to biodegradable biocide agents against marine woodborers. In particular, the present invention relates to novel slow releasing biocide impregnating solutions against marine woodborers, and methods of creating anti marine woodborer environments. | 04-30-2015 |
20160000707 | METHODS OF INHIBITING CATARACTS AND PRESBYOPIA - Described herein are methods of inhibiting or reversing the progression of cataract formation or presbyopia in an eye by administering a γ-crystallin charge masking agent. Both presbyopia and cataracts are caused by aggregation of the soluble crystalline lens proteins called the crystallins. | 01-07-2016 |
20160083336 | FATTY ACID ACYLATED SALICYLATES AND THEIR USES - The invention relates to fatty acid acylated salicylate derivatives; compositions comprising an effective amount of a fatty acid acylated salicylate derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a fatty acid acylated salicylate derivative. | 03-24-2016 |